Clinical Trial Update: Programmed Cell Death Protein-1 (PD-1) Monoclonal Antibody for EBV-HLH and CAEBV as First-line Therapy [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update investigating a PD-1 monoclonal antibody as first-line therapy for EBV-related hemophagocytic lymphohistiocytosis and CAEBV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epstein-barr Virus Infection
• Epstein-barr Virus-associated Lymphoproliferative Disorders

Drugs mentioned

• PD-1 monoclonal antibody

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: EBV Infection | Phase 4 | Status: UNKNOWN